Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (221-230 of 687) with videos related to

Pageof 69
Sort By:
The American Journal of Cardiology|July 17, 2007
Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertensionSanjay Rajagopalan, Faiez Zannad, Anca Radauceanu, et al.
The American Journal of Cardiology|October 26, 2002
Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinanMark S Hansen, Eric B Stanton, Yehia Gawad, et al.
The American Journal of Cardiology|June 14, 2002
Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT)G B John Mancini, Michael E Miller, Gregory W Evans, et al.
American Heart Journal|February 27, 2024
Previous heart failure hospitalization, spironolactone, and outcomes in heart failure with preserved ejection fraction - a secondary analysis of TOPCATBarna Szabo, Lina Benson, Gianluigi Savarese, et al.
Journal of Hypertension|April 24, 2018
Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure: findings from the EPHESUS and OPTIMAAL trialsJoão Pedro Ferreira, Kévin Duarte, Bertram Pitt, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|November 10, 2021
Weight changes in heart failure with preserved ejection fraction: findings from TOPCATJoão Pedro Ferreira, Patrick Rossignol, Brian L Claggett, et al.
American Heart Journal|August 25, 2009
The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunctionMihai Gheorghiade, Sadiya Khan, John E A Blair, et al.
JACC. Heart Failure|December 17, 2018
Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection FractionGianluigi Savarese, Hong Xu, Marco Trevisan, et al.
European Journal of Heart Failure|April 4, 2020
Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failureSusan Stienen, João Pedro Ferreira, Bertram Pitt, et al.
Circulation Research|January 6, 2018
Teasing Apart Heart Failure With Preserved Ejection Fraction Phenotypes With Echocardiographic Imaging: Potential Approach to Research and Clinical PracticeEdgar Argulian, Y Chandrashekhar, Sanjiv J Shah, et al.
Pageof 69

Showing results (221-230 of 687) with videos related to

Sort By:
Pageof 69
The American Journal of Cardiology|July 17, 2007
Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertensionSanjay Rajagopalan, Faiez Zannad, Anca Radauceanu, et al.
The American Journal of Cardiology|October 26, 2002
Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinanMark S Hansen, Eric B Stanton, Yehia Gawad, et al.
The American Journal of Cardiology|June 14, 2002
Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT)G B John Mancini, Michael E Miller, Gregory W Evans, et al.
American Heart Journal|February 27, 2024
Previous heart failure hospitalization, spironolactone, and outcomes in heart failure with preserved ejection fraction - a secondary analysis of TOPCATBarna Szabo, Lina Benson, Gianluigi Savarese, et al.
Journal of Hypertension|April 24, 2018
Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure: findings from the EPHESUS and OPTIMAAL trialsJoão Pedro Ferreira, Kévin Duarte, Bertram Pitt, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|November 10, 2021
Weight changes in heart failure with preserved ejection fraction: findings from TOPCATJoão Pedro Ferreira, Patrick Rossignol, Brian L Claggett, et al.
American Heart Journal|August 25, 2009
The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunctionMihai Gheorghiade, Sadiya Khan, John E A Blair, et al.
JACC. Heart Failure|December 17, 2018
Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection FractionGianluigi Savarese, Hong Xu, Marco Trevisan, et al.
European Journal of Heart Failure|April 4, 2020
Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failureSusan Stienen, João Pedro Ferreira, Bertram Pitt, et al.
Circulation Research|January 6, 2018
Teasing Apart Heart Failure With Preserved Ejection Fraction Phenotypes With Echocardiographic Imaging: Potential Approach to Research and Clinical PracticeEdgar Argulian, Y Chandrashekhar, Sanjiv J Shah, et al.
Pageof 69